Saturday, May 30th 2015
The Cystic Fibrosis Trust has today announced it is committing £500,000 to the UKCFGTC over the next two years to support the infrastructure of the GTC to allow further development of its gene therapy programme for people with cystic fibrosis.
The announcement was made at a meeting focused on the cystic fibrosis community to hear the outcome of the GTC’s Phase 2b clinical trial of the lipid-based therapy. The meeting was arranged because of the extraordinary support the GTC has received to fund its work from the Trust and the wider cystic fibrosis community over the last 15 years.
The new funding announced by the Trust will enable the Consortium to seek additional funding for its continued gene therapy programme including a novel viral-based approach.
The funding we have announced today will help the GTC develop new funding streams to develop its groundbreaking work to create a viral-based gene therapy. This is transformational and costly work but has real potential in the long term.
Gene therapy is one of a number of approaches we at the Trust are funding to help improve and transform the lives of cystic fibrosis. We are not yet at the point where we can say that gene therapy will have clinical use for people with cystic fibrosis but the progress is promising.
We are at a time of extraordinary hope in drug development focused on people with cystic fibrosis. It is unlikely that any one drug or therapy will beat cystic fibrosis alone, and so we are working hard across a range of fronts to bring real impact.
Ed Owen, CF Trust Chief Executive